Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years
NCT07505888 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 660
Last updated 2026-04-01
Summary
The goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 meningococcal conjugate vaccine in healthy children aged 2 to 6 years.
The main questions it aims to answer are:
Is the immune response induced by the investigational vaccine non-inferior to that of the licensed control vaccine, as measured by serum antibody levels? What safety profile does the investigational vaccine have in this pediatric population? Researchers will compare the investigational vaccine group with the control group (licensed ACYW135 polysaccharide vaccine) to determine if the new vaccine provides comparable immune protection with an acceptable safety profile.
Participants will:
Receive a single dose of either the investigational vaccine or the control vaccine by intramuscular injection; Provide two blood samples (before vaccination and 30 days after) for antibody testing; Have their vaccination site and overall health monitored for AE/AR immediately after injection, for 7 days and for 30 days through diary card and follow-up contacts; Be followed for serious adverse events for 6 months after vaccination. A total of 660 participants will be enrolled and randomly assigned in a 1:1 ratio to either the investigational group or the control group.
Conditions
- Epidemic Meningitis
- Meningococcal Vaccines
Interventions
- BIOLOGICAL
-
experimental vaccine
group ACYW135 meningococcal conjugate vaccine
- BIOLOGICAL
-
active comparator vaccine
group ACYW135 meningococcal polysaccharide vaccine
Sponsors & Collaborators
-
Sinovac Biotech Co., Ltd
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 2 Years
- Max Age
- 6 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-03-22
- Primary Completion
- 2026-11-30
- Completion
- 2026-11-30
More Related Trials
-
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China
NCT07135986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
NCT02878291 ·Status: UNKNOWN ·Phase: PHASE1
-
A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine
NCT02481232 ·Status: UNKNOWN ·Phase: PHASE1
-
Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine
NCT07374510 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds
NCT01154088 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
NCT05252715 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population
NCT06011200 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years
NCT06314685 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.
NCT04236960 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine
NCT04689191 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old
NCT02867319 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine
NCT04689165 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
NCT04450498 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
NCT06131554 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds
NCT06700148 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
NCT02003495 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers
NCT03205358 ·Status: COMPLETED ·Phase: PHASE2
-
Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age
NCT04368429 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine
NCT00126984 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects
NCT02591290 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
NCT02003313 ·Status: COMPLETED ·Phase: PHASE3
-
Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old
NCT00196976 ·Status: COMPLETED ·Phase: PHASE2
-
Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers
NCT06284915 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 002
NCT01661738 ·Status: COMPLETED ·Phase: PHASE2
-
Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine
NCT00356369 ·Status: COMPLETED ·Phase: PHASE2